15-12G 1 ea178311-1512g_orionbio.htm FORM 15-12G

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 15

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number: 001-40410

ORION BIOTECH OPPORTUNITIES CORP.

(Exact name of registrant as specified in its charter)

One Vanderbilt Avenue, 26th Floor

New York, NY 10017
(212) 303-1650

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Units, each consisting of one Class A ordinary share, $0.0001 par value, and one-fifth of one redeemable warrant

Class A ordinary shares included as a part of the units

Redeemable warrants included as part of the Units, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50

(Title of each class of securities covered by this Form)

None

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

Rule 12g-4(a)(1)	☒
Rule 12g-4(a)(2)	☐
Rule 12h-3(b)(1)(i)	☒
Rule 12h-3(b)(1)(ii)	☐
Rule 15d-6	☐
Rule 15-22(b)	☐

Approximate number of holders of record of the Units: 2

Approximate number of holders of record of the Warrants: 1

Approximate number of holders of record of the Class A ordinary shares:1

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

Dated: May 11, 2023

	ORION BIOTECH OPPORTUNITIES CORP.

	By:	/s/ Mark Kayal
	Name:	Mark Kayal
	Title:	Chief Financial Officer

SEC Form 15-12G filed by Orion Biotech Opportunities Corp.